Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
Tiziana Life Sciences (Nasdaq: TLSA) announced its participation in BIO-Europe 2024, scheduled for November 4-6 in Stockholm, Sweden. The company will showcase its recent clinical advancements, particularly focusing on its combination study data involving Ozempic, a GLP-1 agonist, and its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody.
CEO Ivor Elrifi highlighted the conference as an opportunity to present their latest clinical findings and engage with potential partners. The company aims to leverage this platform to discuss strategic partnerships and showcase their therapeutic pipeline development, following a successful fundraising round that supports their ongoing Phase 2 studies.
Tiziana Life Sciences (Nasdaq: TLSA) ha annunciato la sua partecipazione a BIO-Europe 2024, in programma dal 4 al 6 novembre a Stoccolma, Svezia. L'azienda presenterà i recenti progressi clinici, concentrandosi in particolare sui dati del suo studio di combinazione che coinvolge Ozempic, un agonista del GLP-1, e il suo principale candidato, foralumab intranasale, un anticorpo monoclonale anti-CD3 completamente umano.
Il CEO Ivor Elrifi ha sottolineato la conferenza come un'opportunità per presentare le ultime scoperte cliniche e interagire con potenziali partner. L'azienda mira a sfruttare questa piattaforma per discutere partnership strategiche e mostrare lo sviluppo del proprio pipeline terapeutico, dopo un round di finanziamento di successo che supporta i loro studi di Fase 2 in corso.
Tiziana Life Sciences (Nasdaq: TLSA) anunció su participación en BIO-Europe 2024, programado para el 4 al 6 de noviembre en Estocolmo, Suecia. La empresa mostrará sus recientes avances clínicos, enfocándose particularmente en los datos de su estudio de combinación que involucra Ozempic, un agonista del GLP-1, y su candidato principal, foralumab intranasal, un anticuerpo monoclonal anti-CD3 completamente humano.
El CEO Ivor Elrifi destacó la conferencia como una oportunidad para presentar sus últimos hallazgos clínicos y relacionarse con posibles socios. La compañía pretende aprovechar esta plataforma para discutir asociaciones estratégicas y mostrar el desarrollo de su pipeline terapéutico, tras una exitosa ronda de financiamiento que apoya sus estudios de Fase 2 en curso.
티치아나 라이프 사이언스(Nasdaq: TLSA)는 스웨덴 스톡홀름에서 11월 4일부터 6일까지 개최되는 BIO-Europe 2024에 참여한다고 발표했습니다. 이 회사는 최근 임상 발전 사항을 선보이며, 특히 GLP-1 작용제인 오젠픽과 주요 후보물질인 비강 포랄루맙, 완전 인간 anti-CD3 단클론 항체의 조합 연구 데이터에 중점을 둘 것입니다.
CEO 아이버 엘리피는 이번 회의가 최신 임상 결과를 발표하고 잠재적 파트너들과 소통할 기회라고 강조했습니다. 이 회사는 이번 플랫폼을 활용해 전략적 파트너십에 대해 논의하고 치료 파이프라인 개발을 보여주며, 진행 중인 2상 연구를 지원하는 성공적인 자금 조달 라운드를 뒤로 하고 있습니다.
Tiziana Life Sciences (Nasdaq: TLSA) a annoncé sa participation à BIO-Europe 2024, prévu du 4 au 6 novembre à Stockholm, Suède. L'entreprise mettra en avant ses récentes avancées cliniques, en se concentrant particulièrement sur les données d'étude de combinaison impliquant Ozempic, un agoniste du GLP-1, et son candidat principal, foralumab intranasal, un anticorps monoclonal anti-CD3 entièrement humain.
Le CEO Ivor Elrifi a souligné que la conférence était une occasion de présenter leurs dernières découvertes cliniques et d'interagir avec des partenaires potentiels. L'entreprise vise à tirer parti de cette plateforme pour discuter de partenariats stratégiques et montrer le développement de son pipeline thérapeutique, à la suite d'un tour de financement réussi qui soutient leurs études de Phase 2 en cours.
Tiziana Life Sciences (Nasdaq: TLSA) gab ihre Teilnahme an BIO-Europe 2024 bekannt, das vom 4. bis 6. November in Stockholm, Schweden, stattfinden wird. Das Unternehmen wird seine jüngsten klinischen Fortschritte präsentieren und dabei insbesondere die Kombinationsstudien-Daten zu Ozempic, einem GLP-1-Agonisten, sowie seinem Hauptkandidaten, intranasalem Foralumab, einem vollständig menschlichen anti-CD3-Monoklonalen Antikörper, in den Fokus rücken.
CEO Ivor Elrifi hob die Konferenz als Gelegenheit hervor, ihre neuesten klinischen Erkenntnisse vorzustellen und mit potenziellen Partnern in Kontakt zu treten. Das Unternehmen beabsichtigt, diese Plattform zu nutzen, um strategische Partnerschaften zu erörtern und die Entwicklung ihres therapeutischen Pipelines zu präsentieren, nachdem eine erfolgreiche Finanzierungsrunde ihre laufenden Phase-2-Studien unterstützt.
- None.
- None.
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation in the BIO-Europe 2024 conference, taking place November 4-6 in Stockholm, Sweden. As part of the conference’s partnering meetings, Tiziana will engage with industry leaders, potential collaborators, and investors to discuss recent clinical progress, including data from its combination study involving Ozempic, a GLP-1 agonist.
The BIO-Europe conference provides a prestigious platform for Tiziana to highlight its strategic advancements to the biopharma community, as well as to expand its partnerships aimed at accelerating the development of its therapeutic pipeline. Key representatives from Tiziana will be available for discussions and will share data from our anti-CD3 and Ozempic combination study, which investigates the potential for enhanced therapeutic effects in targeted conditions. This latest clinical update aligns with Tiziana's commitment to advancing therapies that address significant unmet medical needs.
“The BIO-Europe conference offers an ideal opportunity to highlight our latest clinical findings, including the positive data from our GLP-1 combination study,” said Ivor Elrifi, CEO of Tiziana Life Sciences. “We will be engaging with prospective partners in Stockholm to explore collaborations that will further accelerate our mission of delivering groundbreaking therapies to patients worldwide. We look forward to further advancing our Phase 2 studies following on from the closing of a successful fundraise.”
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program with either an improvement or stability of disease seen within 6 months in all patients. The FDA has recently allowed an additional 20 patients to be enrolled in this EA program. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development, binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been observed in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
FAQ
What will Tiziana Life Sciences (TLSA) present at BIO-Europe 2024?
When and where is Tiziana Life Sciences (TLSA) attending BIO-Europe 2024?
What is the main drug candidate being developed by Tiziana Life Sciences (TLSA)?
What recent study results will Tiziana Life Sciences (TLSA) discuss at BIO-Europe 2024?
